Project Grant R43DK111304

The National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases awarded $3.6 million under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to Anagram Therapeutics Inc. to develop a novel pancreatic enzyme replacement therapy. Specifically, Anagram will engineer lipase enzymes for improved stability against low pH and proteolytic degradation. This will allow for effective digestion of fats in both the stomach and small...

Grant Award Summary SNC Therapeutics, Inc. received a $700,000 Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), effective July 25, 2025 through July 24, 2026. The award funds development and research of rapamycin-loaded polymersomes (RPS), a tolerogenic nanotherapy designed to delay or prevent Type 1 Diabetes (T1D) onset in susceptible populations....

Federal Project Grant Award Summary Syntis Bio Inc. received a $324,984 Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) effective August 1, 2025, through July 31, 2027. The company is developing an oral therapeutic platform to treat homocystinuria (HCU), a rare metabolic disorder caused by cystathionine-β-synthase enzyme deficiency. The core...

Federal Project Grant Award Summary The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded The Leland Stanford Junior University a $681,391 Project Grant, effective March 12, 2026 through February 28, 2030, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The research addresses postbariatric hypoglycemia (PBH), a serious complication affecting up to 38% of bariatric surgery patients, characterized by symptomatic and...

Simmbion LLC was awarded a $255,136 Project Grant from the National Science Foundation's Small Business Technology Transfer program to develop a system for manufacturing drug therapies inside the human body. Over the one-year period from April 2022 to March 2023, the company will genetically engineer symbiotic blood organisms to express and secrete two therapeutic proteins - β-glucocerebrosidase to treat Gaucher's disease and insulin for diabetes treatment. In vitro and in vivo testing will...

Federal Grant Award Summary Persista Bio Inc. received a $287,250 Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) on September 11, 2025, with completion anticipated by August 31, 2026. The award supports the development and manufacturing of clinical-grade cell capsules for the O2LINE™ Implant System, an advanced oxygenated cell encapsulation...

Grant Award Summary The University of Virginia received a $788,831 Project Grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), effective February 1, 2026 through December 31, 2029. The grant funds development of a ketone-aware automated insulin delivery (AID) system designed to enable safe use of sodium-glucose cotransporter inhibitors (SGLT1) in people with Type 1...

Federal Grant Award Summary Persista Bio Inc. received a $3.28 million Project Grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), awarded on September 8, 2025, with a completion date of August 31, 2027. The grant supports advanced preclinical development of the O2LINE System, a safe, anti-fibrotic, oxygenated cell encapsulation device designed for Type 1 Diabetes...

Federal Grant Award Summary United Biotherapeutics LLC received a $615,016 Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), effective September 11, 2025, with completion targeted for August 31, 2027. This Phase I Small Business Technology Transfer (STTR) collaborative research project focuses on developing safer and more efficient delivery systems for...

Federal Project Grant Award Summary Children's Hospital Los Angeles received a $141,087 Project Grant from the National Institute of Diabetes and Digestive and Kidney Diseases under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), awarded on September 30, 2025, with a completion date of April 30, 2027. The grant funds research investigating the role of NGN3 protein in Notch signaling repression during pancreatic endocrinogenesis, with the objective of...